Indications for leukotriene receptor antagonists include patients of what age or older?

Leukotriene receptor antagonists are a class of medications used to manage asthma by blocking the action of leukotrienes, which are inflammatory substances involved in asthma symptoms. The indication for starting these medications in young patients is typically at 12 months of age and older. This age threshold is established because clinical studies have demonstrated their safety and efficacy in this age group for the treatment of asthma and associated conditions.

In younger children, specifically those under 12 months, the evidence supporting the use of leukotriene receptor antagonists is limited, and the potential benefits do not outweigh the risks associated with medication administration in that age range. Therefore, the choice of 12 months is based on both clinical practice guidelines and safety profiles established through research and trials that specifically examined children starting from this age. This careful selection helps ensure that the interventions used are both effective and safe for young children facing asthma management challenges.